Stephen James Ryan Arends , Erin K. McCreary , Matthew Helgeson , Gina Morgan , Shilpa Patkar , Rodrigo Mendes
{"title":"2010-2022年美国引起社区获得性尿路感染的大肠杆菌抗菌素耐药性回顾性分析","authors":"Stephen James Ryan Arends , Erin K. McCreary , Matthew Helgeson , Gina Morgan , Shilpa Patkar , Rodrigo Mendes","doi":"10.1016/j.jgar.2025.08.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>A retrospective analysis of <em>Escherichia coli</em> isolates collected from community-acquired urinary tract infections (UTIs) in the United States for the years 2010–2022 was performed. The data originated from accessing the SENTRY Antimicrobial Surveillance Program, which is a global monitoring program that has been ongoing since 1997 with a purpose of tracking and reporting susceptibility of clinical isolates collected from various infection sources.</div></div><div><h3>Methods</h3><div>Isolates meeting the Centers for Disease Control and Prevention definition for community-acquired UTI were tested for antimicrobial susceptibility against 17 antimicrobial agents using broth microdilution methodology specified by the Clinical & Laboratory Standards Institute guidelines. Isolates were interpreted as susceptible, intermediate, or resistant as appropriate using Clinical & Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing breakpoints and characterized for extended-spectrum <em>β</em>-lactamase and multidrug-resistant phenotypes.</div></div><div><h3>Results</h3><div>The percentage of isolates susceptible to the oral agents amoxicillin-clavulanate, trimethoprim-sulfamethoxazole, and fluoroquinolones was 70%–85% throughout the study period, which crosses the acceptable threshold of 80% for empiric use of trimethoprim-sulfamethoxazole per the 2010 Infectious Disease Society of America guidelines. Higher susceptibility (>90%) was observed for all agents administered via intravenous or intramuscular route. Variation in susceptibility profiles was observed by census region, with the highest resistant rates commonly found in the Middle Atlantic.</div></div><div><h3>Conclusions</h3><div>These data highlight the need for more oral options when treating community-acquired UTIs.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"44 ","pages":"Pages 442-448"},"PeriodicalIF":3.2000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Retrospective analysis of antimicrobial resistance among Escherichia coli causing community-acquired urinary tract infections in the United States from 2010 to 2022\",\"authors\":\"Stephen James Ryan Arends , Erin K. McCreary , Matthew Helgeson , Gina Morgan , Shilpa Patkar , Rodrigo Mendes\",\"doi\":\"10.1016/j.jgar.2025.08.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>A retrospective analysis of <em>Escherichia coli</em> isolates collected from community-acquired urinary tract infections (UTIs) in the United States for the years 2010–2022 was performed. The data originated from accessing the SENTRY Antimicrobial Surveillance Program, which is a global monitoring program that has been ongoing since 1997 with a purpose of tracking and reporting susceptibility of clinical isolates collected from various infection sources.</div></div><div><h3>Methods</h3><div>Isolates meeting the Centers for Disease Control and Prevention definition for community-acquired UTI were tested for antimicrobial susceptibility against 17 antimicrobial agents using broth microdilution methodology specified by the Clinical & Laboratory Standards Institute guidelines. Isolates were interpreted as susceptible, intermediate, or resistant as appropriate using Clinical & Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing breakpoints and characterized for extended-spectrum <em>β</em>-lactamase and multidrug-resistant phenotypes.</div></div><div><h3>Results</h3><div>The percentage of isolates susceptible to the oral agents amoxicillin-clavulanate, trimethoprim-sulfamethoxazole, and fluoroquinolones was 70%–85% throughout the study period, which crosses the acceptable threshold of 80% for empiric use of trimethoprim-sulfamethoxazole per the 2010 Infectious Disease Society of America guidelines. Higher susceptibility (>90%) was observed for all agents administered via intravenous or intramuscular route. Variation in susceptibility profiles was observed by census region, with the highest resistant rates commonly found in the Middle Atlantic.</div></div><div><h3>Conclusions</h3><div>These data highlight the need for more oral options when treating community-acquired UTIs.</div></div>\",\"PeriodicalId\":15936,\"journal\":{\"name\":\"Journal of global antimicrobial resistance\",\"volume\":\"44 \",\"pages\":\"Pages 442-448\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of global antimicrobial resistance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213716525001869\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of global antimicrobial resistance","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213716525001869","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Retrospective analysis of antimicrobial resistance among Escherichia coli causing community-acquired urinary tract infections in the United States from 2010 to 2022
Objective
A retrospective analysis of Escherichia coli isolates collected from community-acquired urinary tract infections (UTIs) in the United States for the years 2010–2022 was performed. The data originated from accessing the SENTRY Antimicrobial Surveillance Program, which is a global monitoring program that has been ongoing since 1997 with a purpose of tracking and reporting susceptibility of clinical isolates collected from various infection sources.
Methods
Isolates meeting the Centers for Disease Control and Prevention definition for community-acquired UTI were tested for antimicrobial susceptibility against 17 antimicrobial agents using broth microdilution methodology specified by the Clinical & Laboratory Standards Institute guidelines. Isolates were interpreted as susceptible, intermediate, or resistant as appropriate using Clinical & Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing breakpoints and characterized for extended-spectrum β-lactamase and multidrug-resistant phenotypes.
Results
The percentage of isolates susceptible to the oral agents amoxicillin-clavulanate, trimethoprim-sulfamethoxazole, and fluoroquinolones was 70%–85% throughout the study period, which crosses the acceptable threshold of 80% for empiric use of trimethoprim-sulfamethoxazole per the 2010 Infectious Disease Society of America guidelines. Higher susceptibility (>90%) was observed for all agents administered via intravenous or intramuscular route. Variation in susceptibility profiles was observed by census region, with the highest resistant rates commonly found in the Middle Atlantic.
Conclusions
These data highlight the need for more oral options when treating community-acquired UTIs.
期刊介绍:
The Journal of Global Antimicrobial Resistance (JGAR) is a quarterly online journal run by an international Editorial Board that focuses on the global spread of antibiotic-resistant microbes.
JGAR is a dedicated journal for all professionals working in research, health care, the environment and animal infection control, aiming to track the resistance threat worldwide and provides a single voice devoted to antimicrobial resistance (AMR).
Featuring peer-reviewed and up to date research articles, reviews, short notes and hot topics JGAR covers the key topics related to antibacterial, antiviral, antifungal and antiparasitic resistance.